Thursday, 27 October 2016

Streptococcus pyogenes Infections Market Consumption 2016 Forecast to 2022

The report provides comprehensive information on the therapeutics under development for Streptococcus pyogenes Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Streptococcus pyogenes Infections and features dormant and discontinued projects.

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

- The report provides a snapshot of the global therapeutic landscape of Streptococcus pyogenes Infections
- The report reviews pipeline therapeutics for Streptococcus pyogenes Infections by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Streptococcus pyogenes Infections therapeutics and enlists all their major and minor projects
- The report assesses Streptococcus pyogenes Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Streptococcus pyogenes Infections

Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Streptococcus pyogenes Infections
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Streptococcus pyogenes Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Streptococcus pyogenes Infections Overview 6
Therapeutics Development 7
Pipeline Products for Streptococcus pyogenes Infections - Overview 7
Pipeline Products for Streptococcus pyogenes Infections - Comparative Analysis 8
Streptococcus pyogenes Infections - Therapeutics under Development by Companies 9
Streptococcus pyogenes Infections - Therapeutics under Investigation by Universities/Institutes 10
Streptococcus pyogenes Infections - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Streptococcus pyogenes Infections - Products under Development by Companies 13
Streptococcus pyogenes Infections - Products under Investigation by Universities/Institutes 14
Streptococcus pyogenes Infections - Companies Involved in Therapeutics Development 15
Absynth Biologics Limited 15
AstraZeneca Plc 16
Emergent BioSolutions Inc. 17
Helix BioMedix, Inc. 18
Sumitomo Dainippon Pharma Co., Ltd. 19
Wellstat Vaccines, LLC 20
Streptococcus pyogenes Infections - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Target 22
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
ATx-201 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
AZ-6142 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
EV-035 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
HB-1345 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
SM-295291 - Drug Profile 35
Contact Info:
Partner Relations & Marketing Manager
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)                                                   

Get in touch:

No comments:

Post a Comment